Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Oxley

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Histopathology|January 24, 2018
Utility of Pathology Imagebase for standardisation of prostate cancer gradingLars Egevad, Brett Delahunt, Daniel M Berney, et al.
European Urology|July 7, 2020
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]David E Neal, Chris Metcalfe, Jenny L Donovan, et al.
European Urology|October 11, 2016
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT TrialThomas J Johnston, Greg L Shaw, Alastair D Lamb, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
NPJ Digital Medicine|May 22, 2026
An evaluation of artificial intelligence assisted prostate biopsy reporting in the Articulate Pro studyLisa Browning, Richard T Colling, Jon Oxley, et al.
BJU International|April 4, 2022
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)Janet Athene Lane, Jenny L Donovan, Grace J Young, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
British Journal of Cancer|June 3, 2016
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committeeEmma L Turner, Chris Metcalfe, Jenny L Donovan, et al.
The Lancet. Oncology|January 14, 2020
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic studyPeter Ström, Kimmo Kartasalo, Henrik Olsson, et al.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Histopathology|January 24, 2018
Utility of Pathology Imagebase for standardisation of prostate cancer gradingLars Egevad, Brett Delahunt, Daniel M Berney, et al.
European Urology|July 7, 2020
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]David E Neal, Chris Metcalfe, Jenny L Donovan, et al.
European Urology|October 11, 2016
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT TrialThomas J Johnston, Greg L Shaw, Alastair D Lamb, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
NPJ Digital Medicine|May 22, 2026
An evaluation of artificial intelligence assisted prostate biopsy reporting in the Articulate Pro studyLisa Browning, Richard T Colling, Jon Oxley, et al.
BJU International|April 4, 2022
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)Janet Athene Lane, Jenny L Donovan, Grace J Young, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
British Journal of Cancer|June 3, 2016
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committeeEmma L Turner, Chris Metcalfe, Jenny L Donovan, et al.
The Lancet. Oncology|January 14, 2020
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic studyPeter Ström, Kimmo Kartasalo, Henrik Olsson, et al.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
Pageof 7